Ketesse (Dexketoprofen)

Dexketoprofen works by reversibly inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which reduces the synthesis of prostaglandins. Lower prostaglandin levels lead to decreased inflammation, reduced peripheral sensitisation of pain receptors, and consequently provide analgesic and antipyretic effects.

The specific dose and frequency of Ketesse are determined by the prescribing clinician based on the severity of pain, the route of administration (intramuscular or intravenous), and the individual patient’s clinical condition. No fixed regimen is provided here.

Safety data for dexketoprofen in pregnancy and lactation are limited, and the product does not have an established pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To request Ketesse, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Ketesse (dexketoprofen) is the S‑enantiomer of ketoprofen, offering a faster onset of analgesia and potentially lower gastrointestinal side‑effects compared with racemic ketoprofen. Compared with ibuprofen or diclofenac, dexketoprofen provides comparable pain relief at lower doses, but the safety profile remains similar to other NSAIDs.

Ketesse must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The vial should remain in its original packaging until use to maintain stability and sterility.

Ketesse is supplied as a sterile injectable solution for intramuscular or intravenous injection. Administration is performed by a qualified healthcare professional, following aseptic technique and the dosage instructions provided by the prescriber.

Serious risks include gastrointestinal ulceration or bleeding, severe allergic reactions such as anaphylaxis, renal impairment, and cardiovascular events like myocardial infarction or stroke. Patients should be monitored closely for signs of these conditions, especially if they have pre‑existing risk factors.

Ketesse should be avoided in patients with known hypersensitivity to dexketoprofen or other NSAIDs, those with active gastrointestinal bleeding or ulcer disease, severe renal or hepatic impairment, and individuals with uncontrolled cardiovascular disease unless specifically directed by a physician.